Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : hNPC01
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : Lilly Asia Ventures
Deal Size : $40.0 million
Deal Type : Series B Financing
Details : The financing will be used to support the IND application of hNPC01 (with stroke as the first indication) both in China and the United States, the following clinical trial, expansion of product pipelines, and development of automated closed-system manufa...
Product Name : hNPC01
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
October 31, 2021
Lead Product(s) : hNPC01
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : Lilly Asia Ventures
Deal Size : $40.0 million
Deal Type : Series B Financing
Reset All
